Foster Dykema Cabot & CO Inc Exelixis, Inc. Transaction History
Foster Dykema Cabot & CO Inc
- $827 Million
- Q3 2023
A detailed history of Foster Dykema Cabot & CO Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Foster Dykema Cabot & CO Inc holds 65 shares of EXEL stock, worth $2,158. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65
Previous 65
-0.0%
Holding current value
$2,158
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding EXEL
# of Institutions
465Shares Held
239MCall Options Held
2.04MPut Options Held
1.29M-
Black Rock Inc. New York, NY33.5MShares$1.11 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.7MShares$985 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA27.1MShares$900 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.2MShares$503 Million0.6% of portfolio
-
State Street Corp Boston, MA12.6MShares$418 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $10.7B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...